Cited by 6,712Pancreatic and Hepatic Oncology ResearchCancer Treatment and PharmacologyPancreatitis Pathology and Treatment

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Open access

Von Hoff, Daniel D., Ervin, Thomas, Arena, Francis P., Chiorean, E. Gabriela, Infante, Jeffrey, Moore, Malcolm, Seay, Thomas, Tjulandin, Sergei A., Ma, Wen Wee, Saleh, Mansoor N., Harris, Marion, Reni, Michele, Dowden, Scot, Laheru, Daniel, Bahary, Nathan, Ramanathan, Ramesh K., Tabernero, Josep, Hidalgo, Manuel, Goldstein, David, Van Cutsem, Eric, Wei, Xinyu, Iglesias, Jose, Renschler, Markus F.·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1304369PMC PMC4631139

Open this paper in CoChat — free account

Abstract

BACKGROUND: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks or gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles). Patients received the study treatment until disease progression. The primary end point was overall survival; secondary end points were progression-free survival and overall response rate. RESULTS: A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was 8.5 months in the nab-paclitaxel-gemcitabine group as compared with 6.7 months in the gemcitabine group (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was 5.5 months in the nab-paclitaxel-gemcitabine group, as compared with 3.7 months in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% versus 7% in the two groups (P<0.001). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days. CONCLUSIONS: In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1304369

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Self-citation
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Self-citation
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
Gradishar, W. J., Tjulandin, S., Davidson, N. G. P., Shaw, H., Desai, N. P., Bhar, P., Hawkins, M., & O’Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,159
Self-citation
Gemcitabine Plus nab -Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Hoff, D. D. V., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N. P., Trieu, V. N., Iglesias, J. L. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,040
Self-citation
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D. B., Steward, W. P., Harper, P., Dunn, J., Smith, C. T., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 822
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P. R., Mariette, C., Bouché, O., Bosset, J.-F., Aparicio, T., Mineur, L., Azzedine, A., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn281 · Cited by 696
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 643

Show all 23 references

Sorted by citations

Items 501–600 of 1,022

Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and ABCC1 transactivation
Wei, L., Lin, Q., Lu, Y., Li, G., Huang, L., Fu, Z., Chen, R., & Zhou, Q. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03574-2 · Cited by 101
Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
Perets, R., Greenberg, O., Shentzer, T., Semenisty, V., Epelbaum, R., Bick, T., Sarji, S., Ben-Izhak, O., Sabo, E., & Hershkovitz, D. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0467 · Cited by 100
AACR Cancer Progress Report 2014
Arteaga, C. L., Adamson, P. C., Engelman, J. A., Foti, M., Gaynor, R. B., Hilsenbeck, S. G., Limburg, P. J., Lowe, S. W., Mardis, E. R., Ramsey, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2123 · Cited by 101
An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)
Lee, S., Kim, Y., Cho, C., Kim, Y. T., Kim, S. M., Hur, S. Y., Kim, J., Kim, B., Kim, S. C., Ryu, H., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.376 · Cited by 100
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
Xia, G., Wang, H., Song, Z., Meng, Q., Huang, X., & Huang, X. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0579-0 · Cited by 100
NF-κB in pancreatic cancer: Its key role in chemoresistance
Li, Q., Yang, G., Feng, M., Zheng, S., Cao, Z., Qiu, J., You, L., Zheng, L., Hu, Y., Zhang, T., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.011 · Cited by 100
CD200 promotes immunosuppression in the pancreatic tumor microenvironment
Choueiry, F., Torok, M. A., Shakya, R., Agrawal, K., Deems, A., Benner, B. N., Hinton, A. M., Shaffer, J. L., Blaser, B. W., Noonan, A. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000189 · Cited by 100
Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use
Dhupal, M., & Chowdhury, D. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s259628 · Cited by 100
Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Seppälä, T. T., Zimmerman, J. W., Suri, R., Zlomke, H., Ivey, G. D., Szabolcs, A., Shubert, C. R., Cameron, J. L., Burns, W. R., Lafaro, K. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4165 · Cited by 102
Consensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 104
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
Hersh, E. M., Vecchio, M. D., Brown, M. P., Kefford, R. F., Loquai, C., Testori, A., Bhatia, S., Gutzmer, R., Conry, R. M., Haydon, A. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv324 · Cited by 100
Self-citation
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
Luheshi, N., Ulrichsen, J. C., Harper, J. A., Mullins, S., Sulikowski, M., Martin, P., Brown, L., Lewis, A. R., Davies, G. C., Morrow, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7610 · Cited by 100
EMT and Stemness—Key Players in Pancreatic Cancer Stem Cells
Rodríguez-Aznar, E., Wiesmüller, L., Sáinz, B., & Hermann, P. C. (2019) · Cancers · doi:10.3390/cancers11081136 · Cited by 99
Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
Patel, H., Okamura, R., Fanta, P. T., Patel, C., Lanman, R. B., Raymond, V. M., Kato, S., & Kurzrock, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0824-4 · Cited by 99
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
Adashek, J. J., Subbiah, V., & Kurzrock, R. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.08.009 · Cited by 99
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)
Ozaka, M., Nakachi, K., Kobayashi, S., Ohba, A., Imaoka, H., Terashima, T., Ishii, H., Mizusawa, J., Katayama, H. G., Kataoka, T., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.014 · Cited by 99
Anticancer nanoparticulate polymer‐drug conjugate
Feng, Q., & Tong, R. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10033 · Cited by 99
Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside
Oettle, H. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.07.003 · Cited by 98
Nanoparticle Albumin-Bound Paclitaxel (Abraxane®)
Desai, N. P. (2016) · Springer eBooks · doi:10.1007/978-981-10-2116-9_6 · Cited by 98
Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
Muranaka, T., Kuwatani, M., Komatsu, Y., Sawada, K., Nakatsumi, H., Kawamoto, Y., Yuki, S., Kubota, Y., Kubo, K., Kawahata, S., et al. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.02.02 · Cited by 98
Hybrid Paclitaxel and Gold Nanorod-Loaded Human Serum Albumin Nanoparticles for Simultaneous Chemotherapeutic and Photothermal Therapy on 4T1 Breast Cancer Cells
Peralta, D. V., Heidari, Z., Dash, S., & Tarr, M. A. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b00858 · Cited by 98
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P. J., Melichar, B., Atkins, J., Nowara, E., Moyé, L. A., Piquemal, D., Ritter, D., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv133 · Cited by 98
Molecular landscape of pancreatic cancer: implications for current clinical trials
Heestand, G. M., & Kurzrock, R. (2015) · Oncotarget · doi:10.18632/oncotarget.2972 · Cited by 97
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Conway, J. R. W., Herrmann, D., Evans, T. J., Morton, J. P., & Timpson, P. (2018) · Gut · doi:10.1136/gutjnl-2018-316822 · Cited by 97
The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer
Brunetto, E., Monte, L. B. D., Balzano, G., Camisa, B., Laino, V., Riba, M., Heltai, S., Bianchi, M. E., Bordignon, C., Falconi, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0521-4 · Cited by 97
Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E
Ma, X., Li, B., Liu, J., Fu, Y., & Luo, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1053-y · Cited by 97
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Overman, M. J., Javle, M. M., Davis, R. E., Vats, P., Kumar‐Sinha, C., Xiao, L., Mettu, N. B., Parra, E. R., Benson, A. B., Lopez, C. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000587 · Cited by 97
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
Nicolle, R., Gayet, O., Duconseil, P., Vanbrugghe, C., Roques, J., Bigonnet, M., Blum, Y., Elarouci, N., Armenoult, L., Ayadi, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.601 · Cited by 97
Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer
Riva, F., Dronov, O. I., Khomenko, D. I., Huguet, F., Louvet, C., Mariani, P., Stern, M., Lantz, O. J., Proudhon, C., Pierga, J., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.006 · Cited by 97
Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells
Gailhouste, L., Liew, L. C., Hatada, I., Nakagama, H., & Ochiya, T. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0487-z · Cited by 97
Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma
Zhao, X., Fan, W., Xu, Z., Chen, H., He, Y., Yang, G. F., Yang, G., Hu, H., Tang, S., Wang, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13212 · Cited by 96
Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice
Peran, I., Dakshanamurthy, S., McCoy, M., Mavropoulos, A., Allo, B. A., Sebastian, A., Hum, N. R., Sprague, S. C., Martin, K. A., Pishvaian, M. J., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.11.044 · Cited by 96
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Huang, X., Zhang, G., Tang, T., Gao, X., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00416-w · Cited by 98
Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer
Whatcott, C. J., Han, H., & Hoff, D. D. V. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000140 · Cited by 96
IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer
Lunardi, S., Lim, S. Y., Muschel, R. J., & Brunner, T. B. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027473 · Cited by 96
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics
Murthy, D., Attri, K. S., & Singh, P. K. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00335 · Cited by 96
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
Tong, H., Fan, Z., Liu, B., & Lu, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-26811-9 · Cited by 96
Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205
Chaudhary, A., Mondal, G., Kumar, V., Kattel, K., & Mahato, R. I. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.007 · Cited by 95
Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Muckenhuber, A., Berger, A. K., Schlitter, A. M., Steiger, K., Konukiewitz, B., Trumpp, A., Eils, R., Werner, J., Friess, H., Esposito, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2180 · Cited by 95
Pancreatic cancer microenvironment: a current dilemma
Uzunparmak, B., & Şahin, İ. H. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0221-1 · Cited by 95
Single molecule characterization of individual extracellular vesicles from pancreatic cancer
Lennon, K. M., Wakefield, D. L., Maddox, A. L., Brehove, M. S., Willner, A. N., Garcia‐Mansfield, K., Meechoovet, B., Reiman, R. A., Hutchins, E. D., Miller, M. M., et al. (2019) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1685634 · Cited by 95
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Al Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00124 · Cited by 94
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2
Macarulla, T. M., Pazo-Cid, R., Guillén‐Ponce, C., López‐López, R., Vera, R., Reboredo, M., Martín, A. J. M., Rivera, F., Beveridge, R. D., Casta, A. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00089 · Cited by 94
Self-citation
New therapeutic targets in pancreatic cancer
Lai, E., Puzzoni, M., Ziranu, P., Pretta, A., Impera, V., Mariani, S., Liscia, N., Soro, P., Musio, F., Persano, M., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101926 · Cited by 94
Systemic Therapy for Metastatic Pancreatic Cancer
Ettrich, T. J., & Seufferlein, T. T. W. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00895-4 · Cited by 94
Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment
Robatel, S., & Schenk, M. (2022) · Cancers · doi:10.3390/cancers14040985 · Cited by 94
NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma
Maithel, S. K., Keilson, J. M., Cao, H. S. T., Rupji, M., Mahipal, A., Lin, B. S.-L., Javle, M. M., Cleary, S. P., Akce, M., Switchenko, J. M., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13809-5 · Cited by 94
JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
Suzuki, S., Okada, M., Shibuya, K., Seino, M., Satō, A., Takeda, H., Seino, S., Yoshioka, T., & Kitanaka, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2693 · Cited by 94
Randomized phase II / III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS ‐ PC Study
Yamaue, H., Tsunoda, T., Tani, M., Miyazawa, M., Yamao, K., Mizuno, N., Okusaka, T., Ueno, H., Boku, N., Fukutomi, A., et al. (2015) · Cancer Science · doi:10.1111/cas.12674 · Cited by 94
Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer
Kawaguchi, K., Miyake, K., Han, Q., Li, S., Tan, Y., Igarashi, K., Kiyuna, T., Miyake, M., Higuchi, T., Oshiro, H., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.016 · Cited by 94
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00505-0 · Cited by 93
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
Giordano, G., Pancione, M., Olivieri, N., Parcesepe, P., Velocci, M., Raimo, T. D., Coppola, L., Toffoli, G., & D'Andrea, M. R. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i32.5875 · Cited by 93
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth
Luna, J., Boni, J., Cuatrecasas, M., Ros, X. B., Núñez-Manchón, E., Gironella, M., Vaquero, E. C., Arbonés, M. L., de la Luna, S., & Fillat, C. (2018) · Gut · doi:10.1136/gutjnl-2018-316128 · Cited by 93
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
Melisi, D., García‐Carbonero, R., Macarulla, T. M., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Kozloff, M. F., Simionato, F., Cleverly, A., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03807-4 · Cited by 93
Self-citation
T‐cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer
He, C., Huang, X., Zhang, Y. L., Lin, X., & Li, S. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.39 · Cited by 93
Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
Gautam, S. K., Batra, S. K., & Jain, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01813-y · Cited by 93
Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT/KEYNOTE-202 trial
Bockorny, B., Macarulla, T., Semenisty, V., Borazanci, E., Feliu, J., Ponz-Sarvise, M., Abad, D. G., Oberstein, P., Alistar, A., Muñoz, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0929 · Cited by 92
Self-citation
Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF 1‐dependent pathway
Chen, K., Qian, W., Li, J., Jiang, Z., Cheng, L., Yan, B., Cao, J., Sun, L., Zhou, C., Lei, M., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12116 · Cited by 92
Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer
Meng, H., & Nel, A. E. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.014 · Cited by 92
Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety
Inoue, Y., Saiura, A., Oba, A., Kawakatsu, S., Ono, Y., Sato, T., Mise, Y., Ishizawa, T., Takahashi, Y., & Ito, H. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3995-3 · Cited by 92
Targeted Therapies for Pancreatic Cancer and Hurdles Ahead
Aslan, M., Shahbazi, R., Ulubayram, K., & Özpolat, B. (2018) · Anticancer Research · doi:10.21873/anticanres.13026 · Cited by 92
Cell cycle dysregulation in cancer
Glaviano, A., Singh, S. K., Lee, E. H. C., Okina, E., Lam, H. Y., Carbone, D., Reddy, E. P., O’Connor, M. J., Koff, A., Singh, G., et al. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100030 · Cited by 98
Pancreatic Adenocarcinoma Management
Jiang, Y., & Sohal, D. P. S. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00328 · Cited by 94
Hippo pathway mediates resistance to cytotoxic drugs
Gujral, T. S., & Kirschner, M. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703096114 · Cited by 91
Genetics of familial and sporadic pancreatic cancer
Wood, L. D., Yurgelun, M. B., & Goggins, M. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.039 · Cited by 91
The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma
García-Reyes, B., Kretz, A.-L., Ruff, J.-P., von Karstedt, S., Hillenbrand, A., Knippschild, U., Henne‐Bruns, D., & Lemke, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103219 · Cited by 91
The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer
Jia, Y., Gu, D., Wan, J., Yu, B., Zhang, X., Chiorean, E. G., Wang, Y., & Xie, J. (2018) · Oncogene · doi:10.1038/s41388-018-0553-0 · Cited by 91
Self-citation
Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
Chan, K., Guo, H., Cheng, S., Beca, J. M., Redmond‐Misner, R., Isaranuwatchai, W., Qiao, L., Earle, C. C., Berry, S. R., Biagi, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2705 · Cited by 91
Pancreatic cancer: The microenvironment needs attention too!
Apte, M. V., Xu, Z., Pothula, S. P., Goldstein, D., Pirola, R. C., & Wilson, J. S. (2015) · Pancreatology · doi:10.1016/j.pan.2015.02.013 · Cited by 91
Self-citation
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites
El‐Deiry, W. S., Vijayvergia, N., Xiu, J., Scicchitano, A., Lim, B., Yee, N. S., Harvey, H. A., Gatalica, Z., & Reddy, S. K. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1113356 · Cited by 91
Management of Hypersensitivity Reactions to Taxanes
Picard, M. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.07.004 · Cited by 91
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2505783 · Cited by 90
Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians
Spadi, R. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.27 · Cited by 90
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
Chiorean, E. G., Hoff, D. D. V., Tabernero, J. M., El-Maraghi, R. H., Ma, W. W., Reni, M., Harris, M., Whorf, R. C., Liu, H. W., Li, J. S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.185 · Cited by 90
Self-citation
Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis
Wright, G. P., Poruk, K. E., Zenati, M. S., Steve, J., Bahary, N., Hogg, M. E., Zuriekat, A., Wolfgang, C. L., Zeh, H. J., & Weiss, M. J. (2016) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-016-3256-2 · Cited by 90
Self-citation
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Caparello, C., Meijer, L. L., Garajová, I., Falcone, A., Large, T. Y. S. L., Funel, N., Geert Kazemier, M., Peters, G. J., Vasile, E., & Giovannetti, E. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i31.6987 · Cited by 90
Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study
Rivera, F., Benavides, M., Gallego-Plazas, J., Guillén‐Ponce, C., Lopez-Martin, J. A., & Küng, M. (2018) · Pancreatology · doi:10.1016/j.pan.2018.10.004 · Cited by 90
CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer
Porcelli, L., Iacobazzi, R. M., Fonte, R., Serratì, S., Intini, A., Solimando, A. G., Brunetti, O., Calabrese, A., Leonetti, F., Azzariti, A., et al. (2019) · Cancers · doi:10.3390/cancers11030330 · Cited by 90
Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment
Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 90
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study
Dean, A. P., Gill, S. S., McGregor, M., Broadbridge, V. T., Järveläinen, H. A., & Price, T. J. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00167-4 · Cited by 90
Phase I pilot study of Wilms tumor gene 1 peptide‐pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer
Mayanagi, S., Kitago, M., Sakurai, T., Matsuda, T., Fujita, T., Higuchi, H., Taguchi, J., Takeuchi, H., Itano, O., Aiura, K., et al. (2015) · Cancer Science · doi:10.1111/cas.12621 · Cited by 89
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
Glassman, D. C., Palmaira, R. L. D., Covington, C. M., Desai, A. M., Ku, G. Y., Li, J., Harding, J. J., Varghese, A. M., O'Reilly, E. M., & Yu, K. H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4605-1 · Cited by 89
ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
Catanese, S., Pentheroudakis, G. E., Douillard, J.-Y., & Lordick, F. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000804 · Cited by 89
Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response
Ashrafizadeh, M., Mohan, C. D., Rangappa, S., Zarrabi, A., Hushmandi, K., Kumar, A. P., Sethi, G., & Rangappa, K. S. (2023) · Medicinal Research Reviews · doi:10.1002/med.21950 · Cited by 89
Single Extracellular VEsicle Nanoscopy
Saftics, A., Abuelreich, S., Romano, E., Ghaeli, I., Jiang, N., Spanos, M., Lennon, K. M., Singh, G. P., Das, S., Keuren‐Jensen, K. R. V., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12346 · Cited by 89
Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer
Togashi, Y., Kogita, A., Sakamoto, H., Hayashi, H., Terashima, M., Velasco, M. A. D., Sakai, K., Fujita, Y., Tomida, S., Kitano, M., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.037 · Cited by 89
Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer
Polvani, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2441 · Cited by 89
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer
Hayashi, H., Kohno, T., Ueno, H., Hiraoka, N., Kondo, S., Saito, M., Shimada, Y., Ichikawa, H., Kato, M., Shibata, T., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000760 · Cited by 88
Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines
Okusaka, T., & Furuse, J. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01666-y · Cited by 88
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX
Peixoto, R. D., Ho, M., Renouf, D. J., Lim, H. J., Gill, S., Ruan, J. Y., & Cheung, W. Y. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000193 · Cited by 88
Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary
Balaban, E. P., Mangu, P. B., & Yee, N. S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.017376 · Cited by 88
Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy
Ge, L., Pan, B., Song, F., Ma, J., Zeraatkar, D., Zhou, J., & Tian, J. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-018175 · Cited by 87
Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
Macherla, S., Laks, S., Naqash, A. R., Bulumulle, A., Zervos, E. E., & Muzaffar, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113505 · Cited by 87
The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment
Lafaro, K. J., & Melstrom, L. G. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.09.009 · Cited by 87
Tumor-penetrating therapy for β5 integrin-rich pancreas cancer
de Mendoza, T. H., Mose, E. S., Botta, G. P., Braun, G. B., Kotamraju, V. R., French, R. P., Suzuki, K., Miyamura, N., Teesalu, T., Ruoslahti, E. I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21858-1 · Cited by 87
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny, B., Grossman, J. E., & Hidalgo, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3452 · Cited by 87
Self-citation
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review
Eshmuminov, D., Aminjonov, B., Palm, R. F., Malleo, G., Schmocker, R. K., Abdallah, R., Yoo, C., Shaib, W. L., Schneider, M. A., Rangelova, E. B., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13353-2 · Cited by 87
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma
Neeße, A., Gress, T. M., Tuveson, D. A., Michl, P., & Krug, S. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s38111 · Cited by 87
Survival Among Patients With Pancreatic Cancer and Long-Standing or Recent-Onset Diabetes Mellitus
Yuan, C., Rubinson, D. A., Qian, Z. R., Wu, C. H., Kraft, P. L., Bao, Y., Ogino, S., Ng, K., Clancy, T. E., Swanson, R. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5688 · Cited by 87

Authors: Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., Harris, M., Reni, M., Dowden, S., Laheru, D., Bahary, N., Ramanathan, R. K., Tabernero, J., Hidalgo, M., Goldstein, D., Van Cutsem, E., Wei, X., Iglesias, J., & Renschler, M. F.
Affiliations: University of Washington (US)
Tennessee Oncology (US)
Princess Margaret Cancer Centre (CA)
Russian Cancer Research Center NN Blokhin (RU)
Translational Genomics Research Institute (US)
Georgia Cancer Specialists (US)
Sidney Kimmel Comprehensive Cancer Center (US)
University of Pittsburgh Medical Center (US)
Universitat Autònoma de Barcelona (ES)
Prince of Wales Hospital (AU)
Celgene (United States) (US)
Bionomics (Australia) (AU)
ORCID: Arena, Francis P.
Chiorean, E. Gabriela
Moore, Malcolm
Tjulandin, Sergei A.
Ma, Wen Wee
Saleh, Mansoor N.
Harris, Marion
Reni, Michele
Laheru, Daniel
Bahary, Nathan
Tabernero, Josep
Hidalgo, Manuel
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-10-31
Volume: 369
Issue: 18
Pages: 1691-1703
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1304369
PMC: PMC4631139
OpenAlex: W2165480504
Cited by: 6,712
References: 23
Citations by year: 2026: 403 · 2025: 491 · 2024: 537 · 2023: 607 · 2022: 614 · 2021: 695 · 2020: 631 · 2019: 531 · 2018: 548 · 2017: 512 · 2016: 423 · 2015: 424 · 2014: 271 · 2013: 15
FWCI: 200.89
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P30CA006973)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords: pancreatic cancer, metastatic pancreatic cancer, nab-paclitaxel, gemcitabine, combination chemotherapy, gemcitabine monotherapy, overall survival, progression-free survival, overall response rate, treatment safety, adverse events, chemotherapy schedule, Karnofsky performance status
MeSH terms: Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Albumins, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Nervous System Diseases, Neutropenia, Pancreatic Neoplasms, Paclitaxel, Disease-Free Survival, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks